Division of OSE Immunotherapeutics SA
Latest From Effimune SAS
Emerging Company Profile: Alexis Peyroles, chief operating officer of OSE Immunotherapeutics outlines the 2016-founded company's plans for commercializing its lead drug, Tedopi (OSE-2102).
French groups OSE Immunotherapeutics and Servier have inked a pact to develop and commercialize the newly formed biotech's interleukin-7 antagonist in ulcerative colitis.
The exercising by Janssen Biotech of an option to develop OSE Immunotherapeutics’ Phase II-ready antibody fragment for autoimmune and transplant-associated disorders will give an early boost to the French biotech that only completed a merger several weeks ago.
Onxeo acquires signal-interfering DNA repair technology for its orphan oncology focus. Sanofi returns auto-injector product to kaleo after product recall.
- Large Molecule
- Therapeutic Areas
- Immune Disorders
- Western Europe
- Parent & Subsidiaries
- OSE Immunotherapeutics SA
- Senior Management
Didier Coquoz, CEO & VP, Bus. Dev.
Marc Moguilewsky, VP, Bus. Dev.
- Contact Info
Phone: 02 40 412834
1 Rue Gaston Veil
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.